Pharmacia Azulfidine
Executive Summary
Sulfasalazine approved Aug. 18 to treat juvenile rheumatoid arthritis in pediatric patients ages six to 16 who respond inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. Efficacy was demonstrated in a 24-week randomized trial. Azulfidine was approved for adult RA in 1996